Upadacitinib Dosing and Safety in Rheumatoid Arthritis

Standard Dosing Regimen

The American College of Rheumatology recommends upadacitinib 15 mg orally once daily for adults with moderate to severe rheumatoid arthritis, which can be used as monotherapy or in combination with conventional synthetic DMARDs, with high strength of evidence 1, 2, 3
The FDA and EMA-approved dose of upadacitinib 15 mg once daily has demonstrated superior efficacy compared to placebo in all RA patient populations, including methotrexate-inadequate responders, biologic DMARD-inadequate responders, and MTX-naïve patients, with moderate to high strength of evidence 1, 2, 3
The 15 mg dose can be administered as monotherapy or combined with background csDMARDs, with high strength of evidence 1, 2, 3

In head-to-head trials, upadacitinib 15 mg plus methotrexate demonstrated superior efficacy compared to adalimumab plus methotrexate, particularly for patient-reported outcomes, with moderate strength of evidence 1, 2, 3
The superiority was primarily observed in ACR50/70 responses and clinical remission rates, with moderate strength of evidence 1, 2, 3

No dose adjustment is required for renal impairment, including severe renal disease, with high strength of evidence 1, 2, 3
Upadacitinib is contraindicated in severe hepatic impairment, with high strength of evidence 1, 2, 3
Dose reduction may be necessary when co-administered with strong CYP3A4 inhibitors, with moderate strength of evidence 4
Dose increase may be required with rifampin or other strong CYP3A4 inducers, with moderate strength of evidence 4

Complete tuberculosis screening with IGRA or tuberculin skin test is mandatory before initiation, with high strength of evidence 4, 6
Baseline laboratory testing should include complete blood count with differential, liver enzymes, renal function, and lipid profile, with moderate strength of evidence 5, 6
Hepatitis B and C testing is required, with moderate strength of evidence 6
Herpes zoster vaccination is recommended before starting therapy in patients ≥18 years, with moderate strength of evidence 7, 6

Patients ≥65 years with cardiovascular risk factors have significantly higher serious infection rates, with moderate strength of evidence 4
According to EMA guidance, tofacitinib and other JAK inhibitors should be used in elderly patients only if no alternative exists, with high strength of evidence 4
FDA black box warnings apply to all JAK inhibitors based on increased risk of major adverse cardiovascular events, venous thromboembolism, malignancies, and death in patients ≥50 years with cardiovascular risk factors, with high strength of evidence 6

Do not use the 30 mg dose for RA, as this is not the approved dose and carries increased safety risks, with high strength of evidence 5, 1, 2
Do not initiate during active serious infections, with high strength of evidence 4, 6
Do not combine with other potent immunosuppressants or biologics beyond established csDMARD combination therapy, with moderate strength of evidence 7